Dr Suchitra Sundaram shares key highlights on frontline time limited and all oral regimens producing deep MRD responses, ...

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...

"Second Winds" refers to how diagnosis and treatment of CLL can lead to "fulfilling lives," says Abbvie's Matt Skryja.

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter ...

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has recently completed a clinical study titled ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

The cancer diagnosis is not a full stop. "Second Winds" profiles CLL patients Christina Fisher, Alejandro Daza, and Jeff Mesky, sharing their journey to thrive. Watch the documentary.

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...